Bristol-Myers Squibb Co., after completing its acquisition of Celgene Corp., is attempting to position itself as a developer of best-in-class and first-in-class chimeric antigen receptor T-cell (CAR-T) therapies for lymphoma and multiple myeloma, including the CD19-targeting lisocabtagene maraleucel (JCAR017, liso-cel) and idecabtagene vicleucel (ide-cel, bb2121) against B-cell maturation antigen (BCMA).
The company presented pivotal trial results in relapsed and refractory B-cell lymphoma for its first CAR-T therapy, liso-cel, at the American Society of Hematology (ASH) meeting in Orlando, FL on 7 and 8 December, which will support a biologic license application (BLA) submission to the US Food and Drug Administration by the end of this year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?